About Illumina
Industry:
Genomics
Founded:
1998
Founders:
David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, Mark Chee
Status:
Public (NASDAQ: ILMN)
Funding & Growth
Total Raised:
N/A
Valuation:
$20B+ market cap
Stage:
Public
Key Investors:
Public markets
✓ Pros
- • Industry leader in sequencing technology
- • Cutting-edge genomics work
- • Strong publication culture
- • Excellent benefits and RSUs
- • San Diego location
✗ Cons
- • Large company bureaucracy
- • Recent layoffs and restructuring
- • Can be siloed between teams
- • Slower decision making